BIO-TECHNE Corp Adjustments to Additional Paid in Capital, Income Tax Benefit from Share-based Compensation
BIO-TECHNE Corp (TECH) reported Adjustments to Additional Paid in Capital, Income Tax Benefit from Share-based Compensation of $514.00 thousand for the 12-month period ending 2017-06-30, per its 10-K/A filed 2019-11-06.
Discontinued › Notes › Compensation Related Costs
us-gaap:AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation · last filed 2019-11-06
- BIO-TECHNE Corp adjustments to additional paid in capital, income tax benefit from share-based compensation for fiscal 2017 was $514.00K, a 9.19% decline from fiscal 2016.
- BIO-TECHNE Corp adjustments to additional paid in capital, income tax benefit from share-based compensation for fiscal 2016 was $566.00K, a 7.97% decline from fiscal 2015.
- BIO-TECHNE Corp adjustments to additional paid in capital, income tax benefit from share-based compensation for fiscal 2015 was $615.00K, a 134.73% increase from fiscal 2014.
- BIO-TECHNE Corp adjustments to additional paid in capital, income tax benefit from share-based compensation for fiscal 2014 was $262.00K, a 249.33% increase from fiscal 2013.
| Period end | Adjustments to Additional Paid in Capital, Income Tax Benefit from Share-based Compensation 12 month |
|---|---|
| 2017-06-30 | $514.00K 10-K/A · filed 2019-11-06 |
| 2016-06-30 | $566.00K 10-K · filed 2018-08-27 |
| 2015-06-30 | $615.00K 10-K · filed 2017-09-07 |
| 2014-06-30 | $262.00K 10-K · filed 2016-08-29 |
| 2013-06-30 | $75.00K 10-K · filed 2015-08-31 |
| 2012-06-30 | $51.00K 10-K · filed 2014-08-29 |
| 2011-06-30 | $847.00K 10-K · filed 2013-08-29 |
| 2010-06-30 | $196.00K 10-K · filed 2012-08-29 |
| 2009-06-30 | $107.00K 10-K · filed 2011-08-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |